Singapore markets closed

Arrowhead Pharmaceuticals, Inc. (ARWR)

NasdaqGS - NasdaqGS Real-time price. Currency in USD
Add to watchlist
22.28-1.01 (-4.33%)
As of 09:58AM EDT. Market open.
Full screen
Trade prices are not sourced from all markets
Previous close23.29
Open22.60
Bid22.17 x 400
Ask22.38 x 600
Day's range22.19 - 22.90
52-week range20.67 - 42.48
Volume48,722
Avg. volume1,263,835
Market cap2.76B
Beta (5Y monthly)0.72
PE ratio (TTM)N/A
EPS (TTM)-2.77
Earnings date09 May 2024
Forward dividend & yieldN/A (N/A)
Ex-dividend dateN/A
1y target est55.38
  • Business Wire

    Arrowhead Pharmaceuticals to Webcast Fiscal 2024 Second Quarter Results

    PASADENA, Calif., April 24, 2024--Arrowhead Pharmaceuticals, Inc. (NASDAQ: ARWR) today announced that it will host a webcast and conference call on May 9, 2024, at 4:30 p.m. ET to discuss its financial results for the fiscal second quarter ended March 31, 2024.

  • Business Wire

    Arrowhead Pharmaceuticals Initiates Phase 1/2a Study of ARO-CFB for Treatment of Complement Mediated Kidney Disease

    PASADENA, Calif., April 24, 2024--Arrowhead Pharmaceuticals, Inc. (NASDAQ: ARWR) announced today that it has dosed the first subjects in a Phase 1/2a clinical trial (NCT06209177) of ARO-CFB, the company’s investigational RNA interference (RNAi) therapeutic, in up to 66 healthy volunteers and patients with complement mediated kidney disease.

  • GlobeNewswire

    Turnstone Biologics Appoints William Waddill to its Board of Directors

    SAN DIEGO, April 16, 2024 (GLOBE NEWSWIRE) -- Turnstone Biologics Corp. (“Turnstone” or the “Company”) (Nasdaq: TSBX), a clinical-stage biotechnology company developing a differentiated approach to treat and cure patients with solid tumors by pioneering selected tumor-infiltrating lymphocyte (Selected TIL) therapy, today announced the appointment of industry veteran William Waddill to the Company’s Board of Directors. The Company also announced that Patrick Machado has stepped down as a member o